-
Matinas Biopharma NYSE American:MTNB Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Location: 1545 Route 206 South, 1545 Route 206 South, Bedminster, NJ, 07921, United States | Website: https://www.matinasbiopharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
183.1K
Cash
6.924M
Avg Qtr Burn
-3.031M
Short % of Float
1.88%
Insider Ownership
12.31%
Institutional Own.
5.90%
Qtr Updated
03/31/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
LYPDISO (MAT9001) (Omega-3 Drug) Details Cardiovascular disease | Failed Discontinued | |
MAT2203 (Oral Amphotericin B) Details Meningitis, Cryptococcal meningitis, Azole-resistant infections, C. krusei infection, Fungal infections, Invasive Aspergillosis | Failed Discontinued |